Lung cancer

The mandated need for an effective diagnostic test

  • More Americans (160,000) will die from lung cancer this year than from breast, prostate, and colorectal cancer combined (American Cancer Society)

 1.6 Million
Will die from lung cancer this year worldwide

Current 5 year

survival rate: 

  • The lack of an early detection method is a key factor contributing to this low rate. The current methods of diagnosis are proven to be ineffective and expensive.

17.7%

55.2%

  • With our detection test via breath analysis, we can target at risk groups and have a much higher chance to pinpoint the cancer early.

5 year survival rate

with early detection:

Percent of Cases by Stage for lung cancer

5%

Unknown

Unstaged

16%

Localized

Confined to primary site

22%

Regional

Spread to regional lymph nodes

57%

Distant

Cancer has metastasized

  • Only 16% of screenings happen when the cancer is localized or in its early phase. Detecting the cancer too late greatly reduces the chance of survival.

In part, this is due to the fact that a robust and cost-effective diagnostic test for lung cancer when it is at the most treatable (i.e., early) stage does not presently exist.

Stay informed about Picomole.

Sign up to our newsletter to get our latest updates.

Navigate

Address

191 Halifax Street

Moncton, NB

E1C 9R6

Info@picomole.com

  • Facebook Social Icon
  • Twitter Social Icon
  • LinkedIn Social Icon

©2018  Picomole Inc. All rights reserved.